Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL
Patrick Brown1, Gerhard Zugmaier2, Lia Gore3
1Johns Hopkins University, Baltimore, MD, USA.
British Journal of Haematology
|December 5, 2019
Abstract
No abstract available in PubMed .


